Bioinformatic analysis reveals a pattern of STAT3-associated gene expression specific to basal-like breast cancers in human tumors
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Bioinformatic analysis reveals a pattern of STAT3-associated gene expression specific to basal-like breast cancers in human tumors
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 111, Issue 35, Pages 12787-12792
Publisher
Proceedings of the National Academy of Sciences
Online
2014-08-20
DOI
10.1073/pnas.1404881111
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- STAT3 mediates TGF-β1-induced TWIST1 expression and prostate cancer invasion
- (2013) Kyung Hwa Cho et al. CANCER LETTERS
- The Emerging Role of Immunosurveillance in Dictating Metastatic Spread in Breast Cancer
- (2013) C. Y. Slaney et al. CANCER RESEARCH
- miR-221/222 Targets Adiponectin Receptor 1 to Promote the Epithelial-to-Mesenchymal Transition in Breast Cancer
- (2013) Michael S. Hwang et al. PLoS One
- STAT3 or USF2 Contributes to HIF Target Gene Specificity
- (2013) Matthew R. Pawlus et al. PLoS One
- miR-221/222: promising biomarkers for breast cancer
- (2013) Wei-Xian Chen et al. TUMOR BIOLOGY
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- STAT3 Is Activated by JAK2 Independent of Key Oncogenic Driver Mutations in Non-Small Cell Lung Carcinoma
- (2012) Brendan D. Looyenga et al. PLoS One
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer
- (2012) Yuh Baba et al. Journal of Oncology
- The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumors
- (2011) Lauren L.C. Marotta et al. JOURNAL OF CLINICAL INVESTIGATION
- Potent and Selective Phosphopeptide Mimetic Prodrugs Targeted to the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 3
- (2011) Pijus K. Mandal et al. JOURNAL OF MEDICINAL CHEMISTRY
- Practical implications of gene-expression-based assays for breast oncologists
- (2011) Aleix Prat et al. Nature Reviews Clinical Oncology
- REVIGO Summarizes and Visualizes Long Lists of Gene Ontology Terms
- (2011) Fran Supek et al. PLoS One
- MicroRNAs miR-221 and miR-222: a new level of regulation in aggressive breast cancer
- (2011) Maitri Y Shah et al. Genome Medicine
- P70S6K 1 regulation of angiogenesis through VEGF and HIF-1α expression
- (2010) Chuan-Xiu Bian et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists
- (2010) Sunil Badve et al. MODERN PATHOLOGY
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differential expression analysis for sequence count data
- (2010) Simon Anders et al. GENOME BIOLOGY
- MicroRNAs in Cancer
- (2009) Ramiro Garzon et al. Annual Review of Medicine
- Jnk signaling pathway-mediated regulation of Stat3 activation is linked to the development of doxorubicin resistance in cancer cell lines
- (2009) Ju-Hwa Kim et al. BIOCHEMICAL PHARMACOLOGY
- The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors
- (2009) Michael Hedvat et al. CANCER CELL
- Targeting STAT3 in cancer: how successful are we?
- (2008) Peibin Yue et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started